Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $47.00 price target on the stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $35.00 price target on the stock.
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares